ClinVar Miner

Submissions for variant NM_001110792.2(MECP2):c.941C>T (p.Pro314Leu)

dbSNP: rs61749723
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Rett and Angelman-like Disorders Variant Curation Expert Panel RCV000133281 SCV002540711 pathogenic Rett syndrome 2022-06-30 reviewed by expert panel curation The c.905C>T p.(Pro302Leu) variant in MECP2 (NM_004992.3) is absent from gnomAD (PM2_supporting). The p.(Pro302Leu) variant has been observed in at least 5 individuals with Rett syndrome or severe neonatal encephalopathy (PMID: 10767337, 30377382, 23696494, 11313756, 16473305, 32472557) (PS4, PP4), where it has been reported as a de novo occurrence (biological parentage unconfirmed) in at least 4 of these individuals (PMID: 10767337, 30377382, 23696494, 11313756) (PM6_very strong). The p.(Pro302Leu) variant occurs in the well-characterized transcriptional repression domain (TRD: aa 302-306) of the MECP2 gene (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). Multiple pathogenic missense variants have been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID: 10814718, 10814719, 10944854, 17387578, 15737703) (PM5). In summary, the c.905C>T p.(Pro302Leu) variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PM6_very strong, PS4, PM1, PM5, PP3, PP4, PM2_supporting).
GeneDx RCV000413239 SCV000490611 pathogenic not provided 2018-02-14 criteria provided, single submitter clinical testing The P302L missense variant in the MECP2 gene has been reported multiple times previously in association with Rett syndrome (Cheadle et al., 2000; RettBASE). It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The P302L variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a conserved position predicted to be within the transcriptional repression domain (TRD). Multiple different missense variants at the same residue as well as multiple missense variants in nearby residues have been reported in the Human Gene Mutation Database in association with Rett syndrome (Stenson et al., 2014), supporting the functional importance of this region of the protein.
Molecular Diagnostics Lab, Nemours Children's Health, Delaware RCV000133281 SCV000537170 likely pathogenic Rett syndrome 2015-06-30 criteria provided, single submitter clinical testing
Invitae RCV000754784 SCV003445287 pathogenic Severe neonatal-onset encephalopathy with microcephaly 2023-08-04 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Pro302 amino acid residue in MECP2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10944854, 15737703, 16225173, 17387578). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MECP2 protein function. ClinVar contains an entry for this variant (Variation ID: 143738). This missense change has been observed in individual(s) with Rett syndrome (PMID: 10767337). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 302 of the MECP2 protein (p.Pro302Leu).
Centre for Population Genomics, CPG RCV000133281 SCV004232210 pathogenic Rett syndrome 2024-01-09 criteria provided, single submitter curation This variant has been collected from RettBASE and curated to current modified ACMG/AMP criteria. Based on the classification scheme defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders Specifications to the ACMG/AMP Variant Interpretation Guidelines VCEP 3.0, this variant is classified as pathogenic. At least the following criteria are met: This variant is absent from gnomAD (PM2_Supporting). This variant has been identified as a de novo occurrence in at least an individual with Rett syndrome without confirmation of paternity and maternity (PM6) PMID: 10767337, ClinVar Variation ID: 143738 Has been observed in at least 5 individuals with phenotypes consistent with MECP2-related disease (PS4, PP4). (PMID: 16473305 , ClinVar Variation ID: 143738) Occurs in the well-characterized Transcriptional repression domain (TRD) of MECP2 (PM1). Computational prediction analysis tools suggests a deleterious impact (REVEL score>= 0.75) (PP3).
RettBASE RCV000133281 SCV000188289 uncertain significance Rett syndrome 2008-01-21 no assertion criteria provided curation
The Raphael Recanati Genetics Institute, Rabin Medical Center RCV000754784 SCV000882666 pathogenic Severe neonatal-onset encephalopathy with microcephaly 2018-09-13 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.